

Sample ID	Age	Source	Sub-type	Grade	Ki67	ER (%)	PgR (%)	HER2	EGFR	Adjuvant Chemotherapy	Adjuvant Endocrine	Disease Free Interval in Months	Metastatic Endocrine	Duration in Months [Response]	Metastatic Chemotherapy	Duration in Months [Response]	Figure Number
BB3RC1	50	PE	ILC	2	83.3	0	0	Neg	Neg	EC-T	Nil	12	Nil	NA	Nil	NA	1b
BB3RC2	38	PE	IDC	3	95	0	0	Neg	3+	E-CMF	Nil	6	Nil	NA	Paclitaxel + Herceptin	3 [PD]	1b
															Capecitabine	3 [PD]	
															Vinorelbine	2 [PD]	
															Gemcitabine + Carboplatin	3 [PD]	
BB3RC3	59	PE	ILC	1	29.3	90	5	Neg	1+	FEC-D	Tamoxifen	20	Letrozole	14 [SD]	Nil	NA	1b
													Exemestane	4 [PD]			
													Fulvestrant	3 [PD]			
BB3RC4	54	Ascites	IDC	2	37.7	75	13	Neg	1+	Epirubicin Capecitabine	Letrozole	7	Nil	NA	Nil	NA	1b, 5b
BB3RC5	37	PE	IDC	3	42	90	20	Neg	Neg	FEC-T	Tamoxifen + Goserelin	30	Letrozole + Goserelin	12 [SD]	Docetaxel + Cyclophosphamide	10 [PR]	5b
													Fulvestrant	3 [PD]			
BB3RC18	63	PE	IDC	3	42.3	95	25	Neg	Neg	Nil	Tamoxifen	42	Letrozole	10 [SD]	Doxorubicin + Cyclophosphamide	4 [PR]	3c, 4a
													Exemestane	3 [PD]	Capecitabine	4 [PR]	
													Megace	4 [PD]			
BB3RC19	78	PE	IDC	2	1	83	18	Neg	Neg	Nil	Tamoxifen 5yr	144	Letrozole	6 [PD]	Nil	NA	3c
BB2RC1	82	Solid	IDC	3	UN	100	0	UN	UN	Nil	Letrozole	Non- cancer related death (24 months)	NA	NA	NA	NA	1b
BB2RC2	74	Solid	IDC	2	UN	100	100	UN	UN	Nil	Tamoxifen	No relapse	NA	NA	NA	NA	1b, 5b

**Supplemental Table S1**

Details of primary samples used in this study. Figure number relates to experiment each sample was used in. **UN** unknown, **PE** pleural effusion, **IDC** invasive ductal carcinoma, **ILC** invasive lobular carcinoma, **ER** oestrogen receptor alpha, **PgR** progesterone receptor, **Neg** negative, **NA** not applicable, **PD** progressive disease, **SD** stable disease, **PR** partial response, **FEC-T** 5FU, Epirubicin, Cyclophosphamide - Taxotere, **E-CMF** Epirubicin – Cyclophosphamide, Methotrexate, 5FU, **EC-T** Epirubicin, Cyclophosphamide – Taxotere.